Floatz logo

PARAFFINUM FLAVUM

Breast Ductal Carcinoma In Situ

City of Hope Medical CentermixturePhase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Breast Ductal Carcinoma In Situ cohort.

Asset / SponsorPhaseRating
Arimidex
Alliance for Clinical Trials in Oncology
Phase 3BB
Letrozole
Alliance for Clinical Trials in Oncology
Phase 3BB
(Z)-Endoxifen
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Phase 2BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB

View all 21 →

Same molecule, other indications

PARAFFINUM FLAVUM is also rated in:

Radiation-Induced DermatitisDormant
CC
Indicative ·
43 / 100
View asset →
Invasive Breast CarcinomaDormant
CC
Indicative ·
40 / 100
View asset →
Breast CarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →